ProShares UltraShort Nasdaq Biotechnology(BIS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$12
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BIS

11/20/2026: BIS (1-star) is currently NOT-A-BUY. Pass it for now.

ProShares UltraShort Nasdaq Biotechnology (BIS) is an inverse leveraged exchange-traded fund engineered to achieve -2x the daily performance of the Nasdaq Biotechnology Index via swap agreements. Backed by ProShare Advisors, it features standard operational costs with a 0.95% expense ratio, but struggles with a small asset base (~$1.9M) and low trading volume. Its primary use case is short-term tactical hedging or bearish speculation during expected biotechnology downturns. Key risks include severe long-term compounding decay, high sector volatility, and acute sensitivity to positive clinical or macroeconomic catalysts. It is designed exclusively for experienced, active traders rather than long-term buy-and-hold investors, requiring close intraday monitoring.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitGrowth investors seek capital appreciation, whereas BIS is an inverse fund designed to lose value during sector growth phases.
Momentum investorStrong fit while signal remains positiveShort-term momentum traders capitalizing on sudden, sharp biotech downturns can utilize BIS for tactical bearish plays.
Value investorWeak fitValue investors focus on fundamental underlying asset worth rather than short-term derivative-based hedging tools.
Dividend/Income investorWeak fitThe fund does not target fundamental equity income and is unsuited for income-generation goals.
Low-risk investorWeak fitHigh volatility and severe compounding decay make this product exceptionally risky for conservative investors.

Investor Profile

Ideal Investor Profile

Sophisticated short-term tactical traders or risk managers seeking intraday or very short-term inverse exposure to the biotechnology sector.

Suitability

Strictly suited for active daily trading and hedging; entirely inappropriate for buy-and-hold or long-term retail investors due to compounding decay.

Risk Profile

Risk factorLevelWhy it matters
VolatilityHighAmplified daily tracking targets cause rapid and severe price fluctuations.
Market riskHighAdverse upward movements in the biotechnology sector result in immediate, steep losses.
ConcentrationHighThe underlying index focuses narrowly on the biotechnology and pharmaceutical industries.
Tracking/expenseMedium / highCompounding effects over holding periods longer than one day cause material deviation from the nominal -2x objective.
LiquidityHighLow assets and modest trading volumes can introduce execution friction and wider spreads.
Business/sector qualityMedium / highBiotech stocks are heavily sensitive to binary clinical events and regulatory decisions.

Sector & Industry Intelligence

This fund is not assigned to one sector.

Risk Analysis

Volatility

BIS exhibits extreme historical volatility due to its -2x daily leverage target compounding against a volatile underlying sector.

Market Risk

Subject to intense directional market risk, where upward momentum in biotechnology stocks results in rapid capital loss.

What the ETF Owns

Exposure TypeExposureWeight (%)Retail Investor Read
DerivativesNasdaq Biotechnology Index Swap Agreements — seeks -2x daily return65Provides the structural -2x daily inverse exposure to the performance of the underlying biotechnology index.
Cash/collateralU.S. Dollar Cash & Equivalents35Serves as collateral backing the fund's swap contracts and daily operational liquidity.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type ETF
Historic Profit -27.41%
Avg. Invested days 26
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
ETF Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026
Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.